Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;51(1):e13436.
doi: 10.1111/eci.13436. Epub 2020 Nov 7.

Clinical profile and prognosis in patients on oral anticoagulation before admission for COVID-19

José Miguel Rivera-Caravaca  1 , Iván J Núñez-Gil  2 , David Vivas  2 , María C Viana-Llamas  3 , Aitor Uribarri  4 , Víctor Manuel Becerra-Muñoz  5 , Daniela Trabattoni  6 , Inmaculada Fernández Rozas  7 , Gisela Feltes  8 , Javier López-Pais  9 , Ibrahim El-Battrawy  10 , Carlos Macaya  2 , Antonio Fernandez-Ortiz  2 , Vicente Estrada  2 , Francisco Marín  1 ; HOPE COVID-19 Investigators
Affiliations

Clinical profile and prognosis in patients on oral anticoagulation before admission for COVID-19

José Miguel Rivera-Caravaca et al. Eur J Clin Invest. 2021 Jan.

Abstract

Background: The coronavirus disease 2019 (COVID-19) shows high morbidity and mortality, particularly in patients with concomitant cardiovascular diseases. Some of these patients are under oral anticoagulation (OAC) at admission, but to date, there are no data on the clinical profile, prognosis and risk factors of such patients during hospitalization for COVID-19.

Design: Subanalysis of the international 'real-world' HOPE COVID-19 registry. All patients with prior OAC at hospital admission for COVID-19 were suitable for the study. All-cause mortality was the primary endpoint.

Results: From 1002 patients included, 110 (60.9% male, median age of 81.5 [IQR 75-87] years, median Short-Form Charlson Comorbidity Index [CCI] of 1 [IQR 1-3]) were on OAC at admission, mainly for atrial fibrillation and venous thromboembolism. After propensity score matching, 67.9% of these patients died during hospitalization, which translated into a significantly higher mortality risk compared to patients without prior OAC (HR 1.53, 95% CI 1.08-2.16). After multivariate Cox regression analysis, respiratory insufficiency during hospitalization (HR 6.02, 95% CI 2.18-16.62), systemic inflammatory response syndrome (SIRS) during hospitalization (HR 2.29, 95% CI 1.34-3.91) and the Short-Form CCI (HR 1.24, 95% CI 1.03-1.49) were the main risk factors for mortality in patients on prior OAC.

Conclusions: Compared to patients without prior OAC, COVID-19 patients on OAC therapy at hospital admission showed lower survival and higher mortality risk. In these patients on OAC therapy, the prevalence of several comorbidities is high. Respiratory insufficiency and SIRS during hospitalization, as well as higher comorbidity, pointed out those anticoagulated patients with increased mortality risk.

Keywords: Coronavirus disease 2019; SARS-CoV-2; anticoagulant; atrial fibrillation; thrombosis; venous thromboembolism.

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

Figure 1
Figure 1
Mortality‐free survival depending on the previous use of oral anticoagulation therapy. Solid line = patients without prior oral anticoagulation at hospital admission. Dashed line = patients on prior oral anticoagulation at hospital admission
Figure 2
Figure 2
Cumulative hazard with 95% confidence interval of the predictive model for the primary outcome in patients with prior oral anticoagulation therapy
See this image and copyright information in PMC

References

    1. World Health Organization . WHO announces COVID‐19 outbreak a pandemic [updated 12–03‐2020; cited 17–04‐2020]. Available from: http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-.... Accessed on April 17, 2020.
    1. Clerkin KJ, Fried JA, Raikhelkar J, et al. Coronavirus disease 2019 (COVID‐19) and cardiovascular disease. Circulation. 2020;141(20):1648‐1655. - PubMed
    1. Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID‐19). JAMA Cardiol. 2020;5(7):811‐818. - PMC - PubMed
    1. European Society of Cardiology . ESC Guidance for the Diagnosis and Management of CV Disease during the COVID‐19 Pandemic [updated 21–04‐2020; cited 2020 10–05‐2020]. Available from: https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-.... Accessed on May 10, 2020.
    1. Malaty M, Kayes T, Amarasekera AT, Kodsi M, MacIntyre CR, Tan TC. Incidence and treatment of arrhythmias secondary to coronavirus infection in humans: a systematic review. Eur J Clin Invest. 2020:e13428. Epub Ahead Of Print. - PMC - PubMed

MeSH terms